West Pharmaceutical (WST) announced that the company has reached a definitive agreement to sell all manufacturing and supply rights for SmartDose 3.5mL On-Body Delivery System and associated facilities to AbbVie (ABBV) for total consideration of $112.5M at close, subject to working capital and other adjustments. The definitive agreement, which is subject to certain closing conditions, is expected to close in mid-2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST: